Positron emission tomography imaging using an inverse agonist radioligand to assess cannabinoid CB1 receptors in rodents

NeuroImage

Volumn 41, Issue 3, 2008, Pages 690-698

  Terry, Garth ^a,c   Liow, Jeih San ^a   Chernet, Eyassu ^b   Zoghbi, Sami S ^a   Phebus, Lee ^b   Felder, Christian C ^b   Tauscher, Johannes ^b   Schaus, John M ^b   Pike, Victor W ^a   Halldin, Christer ^c   Innis, Robert B ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 (3 METHOXYPHENYL) 3 (1 PHENYLETHYLAMINO) 1 (4 TRIFLUOROMETHYLPHENYL)PYRROLIDIN 2 ONE; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CARBON 11; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; GLYCOPROTEIN P; METHANANDAMIDE; RADIOLIGAND; RIMONABANT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; ELECTROENCEPHALOGRAM; KNOCKOUT MOUSE; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN TRANSPORT; RADIOASSAY; RAT; RECEPTOR DENSITY;

ANIMALS; ARACHIDONIC ACIDS; BINDING, COMPETITIVE; BRAIN CHEMISTRY; CARBON RADIOISOTOPES; ENDOCANNABINOIDS; MALE; MASS SPECTROMETRY; MICE; POLYUNSATURATED ALKAMIDES; POSITRON-EMISSION TOMOGRAPHY; PYRROLIDINONES; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1;

EID: 44449105153     PISSN: 10538119     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2008.03.004     Document Type: Article

References (33)

1. Abadji V., Lin S., Taha G., Griffin G., Stevenson L.A., Pertwee R.G., and Makriyannis A. (R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J. Med. Chem. 37 (1994) 1889-1893
2. 1 receptors in mouse brain and N18TG2 neuroblastoma cells. Biochem. Pharmacol. 53 (1997) 207-214
3. Adams I.B., Ryan W., Singer M., Thomas B.F., Compton D.R., Razdan R.K., and Martin B.R. Evaluation of cannabinoid receptor binding and in vivo activities for anandamide analogs. J. Pharmacol. Exp. Ther. 273 (1995) 1172-1181
4. Adams I.B., Compton D.R., and Martin B.R. Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J. Pharmacol. Exp. Ther. 284 (1998) 1209-1217
5. Ambudkar S.V., Dey S., Hrycyna C.A., Ramachandra M., Pastan I., and Gottesman M.M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 39 (1999) 361-398
6. 18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 9800-9805
7. 2, serotonin 2A and NK-1 receptors as examples. Life Sci. 78 (2005) 340-346
8. Cherry S.R. The 2006 Henry N Wagner lecture: of mice and men (and positrons)-advances in PET imaging technology. J. Nucl. Med. 47 (2006) 1735-1745
9. Dickason-Chesterfield A.K., Kidd S.R., Moore S.A., Schaus J.M., Liu B., Nomikos G.G., and Felder C.C. Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors. Cell Mol. Neurobiol. 26 (2006) 407-423
10. Fride E., and Mechoulam R. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur. J. Pharmacol. 231 (1993) 313-314
11. Gifford A.N., Bruneus M., Gatley S.J., Lan R., Makriyannis A., and Volkow N.D. Large receptor reserve for cannabinoid actions in the central nervous system. J. Pharmacol. Exp. Ther. 288 (1999) 478-483
12. Grotenhermen F. Cannabinoids. Curr. Drug Targets CNS Neurol. Disord. 4 (2005) 507-530
13. 1 receptor using SR141716A, a central cannabinoid receptor antagonist. Neurosci Lett. 220 (1996) 101-104
14. Innis R.B., Cunningham V.J., Delforge J., Fujita M., Gjedde M., Gunn R.N., Holden J., Houle S., Huang S.C., Ichise M., Iida H., Ito H., Kimura Y., Koeppe R.A., Knudsen G.M., Knuuti J., Lammertsma A.A., Laruelle M., Logan J., Maguire R.P., Mintun M.A., Morris E.D., Parsey R., Price J.C., Slifstein M., Sossi V., Suhara T., Votaw J.R., Wong D.F., and Carson R.E. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J. Cereb. Blood Flow Metab. 27 (2007) 1533-1539
15. Johnson C.A., Seidel J., Vaquero J.J., Pascau J., Desco M., and Green M.V. Exact positioning for OSEM reconstructions on the ATLAS depth-of-interaction small animal scanner. Mol. Imaging Biol. 4 (2002) S22
16. Katoh M., Suzuyama N., Takeuchi T., Yoshitomi S., Asahi S., and Yokoi T. Kinetic analyses for species differences in P-glycoprotein-mediated drug transport. J. Pharm. Sci. 95 (2006) 2673-2683
17. Liow J., Seidel J., Johnson C.A., Toyama H., Green M.V., and Innis R.B. A single slice rebinning/2D exact positioning OSEM reconstruction for the NIH ATLAS small animal PET scanner. J. Nucl. Med. 44 (2003) 163P
18. 11C](R)-(-)-RWAY. Synapse. 61 (2007) 96-105
19. 1 receptor constitutes an agonist/inverse agonist binding region. J. Med. Chem. 46 (2003) 5139-5152
20. McGregor I.S., Issakidis C.N., and Prior G. Aversive effects of the synthetic cannabinoid CP 55,940 in rats. Pharmacol. Biochem. Behav. 53 (1996) 657-664
21. Murphy J.W., and Kendall D.A. Integrity of extracellular loop 1 of the human cannabinoid receptor 1 is critical for high-affinity binding of the ligand CP 55,940 but not SR 141716A. Biochem. Pharmacol. 65 (2003) 1623-1631
22. Pacher P., Batkai S., and Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 58 (2006) 389-462
23. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates. 4th ed (1998), Academic Press, New York
24. Paxinos G., and Franklin K.B.J. The Mouse Brain in Stereotaxic Coordinates (2001), Academic Press, San Diego
25. 1 receptors. Life Sci. 76 (2005) 1307-1324
26. Piomelli D., Tarzia G., Duranti A., Tontini A., Mor M., Compton T.R., Dasse O., Monaghan E.P., Parrott J.A., and Putman D. Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev. 12 (2006) 21-38
27. 1) cannabinoid receptor antagonist, in rodent brain. Life Sci. 58 (1996) 1239-1247
28. Schinkel A.H., Wagenaar E., Mol C.A., and van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin Invest. 97 (1996) 2517-2524
29. Seidel J., Vaquero J.J., and Green M.V. Resolution uniformity and sensitivity of the NIH ATLAS small animal PET scanner: comparison to simulated LSO scanners without depth-of-interaction capability. IEEE Trans. Nucl. Sci. 50 (2003) 1347-1350
30. Van Gaal L.F., Rissanen A.M., Scheen A.J., Ziegler O., and Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365 (2005) 1389-1397
31. 1 receptor antagonism-or inverse agonism-as potential obesity treatment and other therapeutic use. J. Clin. Pharm. Ther. 32 (2007) 209-231
32. 1 receptors in nonhuman primate brain. Neuropsychopharmacology 33 (2008) 259-269
33. 18F-FECNT: a polar radiometabolite confounds brain radioligand measurements. J Nucl Med. 47 (2006) 520-527